T1	p 176 184	asthma .
T2	p 246 273	patients with asthma poorly
T3	p 688 709	in adult asthmatics .
T4	p 718 741	Sixty-six subjects were
T5	i 6 93	Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast :
T6	i 297 320	inhaled corticosteroids
T7	i 433 451	placebo-controlled
T8	i 504 601	salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M )
T9	i 756 767	SFC or FP/M
T10	i 1386 1390	FP/M
T11	i 1690 1697	( SOLTA
T12	o 153 172	airway inflammation
T13	o 388 407	airway inflammation
T14	o 605 687	sputum inflammatory markers , airway responsiveness , lung function , and symptoms
T15	o 818 841	neutrophil , eosinophil
T16	o 868 896	, and epithelial cell levels
T17	o 900 907	induced
T18	o 915 916	.
T19	o 960 1045	other sputum markers of airway inflammation , airway responsiveness , symptom control
T20	o 1048 1067	and lung function .
T21	o 1129 1154	sputum inflammatory cells
T22	o 1200 1223	in sputum eosinophils .
T23	o 1254 1284	improved airway responsiveness
T24	o 1324 1336	improvements
T25	o 1340 1373	symptom control and lung function
T26	o 1420 1430	reductions
T27	o 1588 1594	airway
T28	o 1619 1642	PEF and symptom control
T29	o 1681 1689	SAM40030